Medtronic reported a 3% decrease in revenue, totaling $7.6 billion, but experienced a 2% increase on an organic basis. GAAP diluted EPS decreased by 67% to $0.32, while non-GAAP diluted EPS decreased by 2% to $1.30. The company has updated its guidance and anticipates organic revenue growth to accelerate in the second half of the fiscal year.
Revenue of $7.6 billion decreased 3% as reported and increased 2% organic
GAAP diluted EPS of $0.32 decreased 67%; non-GAAP diluted EPS of $1.30 decreased 2%
Company updates guidance; expects organic revenue to accelerate in second half
Second quarter U.S. revenue of $4.069 billion represented 54% of company revenue and increased 2% as reported and 1% organic.
The company expects fiscal year 2023 second half revenue growth of 3.5% to 4.0% on an organic basis. The company now expects fiscal year 2023 diluted non-GAAP EPS in the range of $5.25 to $5.30. EPS guidance includes an estimated 18 cent negative impact from foreign currency at rates as of the beginning November.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance